{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:39:07Z","timestamp":1793299147518,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.metabol.2024.156066","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T15:01:51Z","timestamp":1731855711000},"page":"156066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?"],"prefix":"10.1016","volume":"162","author":[{"given":"Fernando","family":"Bril","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Elbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156066_bb0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1573402116999201209203534","article-title":"Nonalcoholic fatty liver disease (NAFLD) for primary care providers: beyond the liver","volume":"17","author":"Godinez-Leiva","year":"2021","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.metabol.2024.156066_bb0010","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.metabol.2024.156066_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0020","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/hep.26988","article-title":"Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis","volume":"59","author":"Bril","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156066_bb0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156066_bb0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156066_bb0035","unstructured":"National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: common cancer sites. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/common.html. [Last accessed: 06\/10\/2024]."},{"key":"10.1016\/j.metabol.2024.156066_bb0040","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091697","article-title":"A review of the paradigmatic role of adipose tissue in renal cancer: fat measurement and tumor behavior features","volume":"16","author":"Faiella","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.metabol.2024.156066_bb0050","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/ijc.22526","article-title":"Low adiponectin levels are associated with renal cell carcinoma: a case-control study","volume":"120","author":"Spyridopoulos","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.metabol.2024.156066_bb0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2008.02.044","article-title":"Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney","volume":"54","author":"Pinthus","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0060","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.juro.2006.06.039","article-title":"Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma","volume":"176","author":"Horiguchi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0065","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jnci\/djt310","article-title":"An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma","volume":"105","author":"Hakimi","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.metabol.2024.156066_bb0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","volume":"68","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"issue":"788\u201396","key":"10.1016\/j.metabol.2024.156066_bb0075","article-title":"Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China","volume":"19","author":"Wang","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156066_bb0080","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/liv.15195","article-title":"Risk of hepatic and extrahepatic cancer in NAFLD: a population-based cohort study","volume":"42","author":"Bjorkstrom","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.156066_bb0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.21037\/hbsn-21-546","article-title":"Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China","volume":"12","author":"Yuan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.metabol.2024.156066_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.985858","article-title":"The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2024.156066_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.928619","article-title":"Association between metabolic syndrome and risk of renal cell cancer: a meta-analysis","volume":"12","author":"Du","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0100","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/ije\/dyv001","article-title":"Metabolic risk score and cancer risk: pooled analysis of seven cohorts","volume":"44","author":"Stocks","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.metabol.2024.156066_bb0105","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/biomedicines11041110","article-title":"Comorbidities and malignancy among NAFLD patients compared to the general population, a nation-based study","volume":"11","author":"Abu-Freha","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.metabol.2024.156066_bb0110","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00004836-200304000-00015","article-title":"Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study","volume":"36","author":"Sorensen","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156066_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13209-2","article-title":"Clinical implication of ectopic liver lipid accumulation in renal cell carcinoma patients without visceral obesity","volume":"7","author":"Watanabe","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156066_bb0120","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156066_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002080","article-title":"Nonalcoholic cirrhosis increased risk of digestive tract malignancies: a population-based cohort study","volume":"94","author":"Sun","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2024.156066_bb0130","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.metabol.2024.156066_bb0135","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comperat","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156066_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.amjms.2020.04.031","article-title":"Nonalcoholic fatty liver disease associated with bladder cancer","volume":"360","author":"Chiang","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.metabol.2024.156066_bb0145","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.2147\/CMAR.S181178","article-title":"The association between metabolic syndrome and bladder cancer susceptibility and prognosis: an updated comprehensive evidence synthesis of 95 observational studies involving 97,795,299 subjects","volume":"10","author":"Peng","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.metabol.2024.156066_bb0150","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2022050","article-title":"The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies","volume":"44","author":"Ahmadinezhad","year":"2022","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.metabol.2024.156066_bb0155","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s40618-024-02417-z","volume":"47","author":"Natalicchio","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2024.156066_bb0160","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156066_bb0165","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156066_bb0170","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: a systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156066_bb0175","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jgh.15350","article-title":"The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development","volume":"36","author":"Yamamoto","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156066_bb0180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1530\/ERC-14-0036","article-title":"Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence","volume":"21","author":"Choi","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.metabol.2024.156066_bb0185","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: a literature review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.metabol.2024.156066_bb0190","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/oby.23960","article-title":"Noninvasive tests to identify liver fibrosis in metabolic dysfunction-associated steatotic liver disease are affected by race","volume":"32","author":"Bril","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2024.156066_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251449","article-title":"Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes","volume":"16","author":"Dayton","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156066_bb0200","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.juro.2018.03.135","article-title":"Liver disease in men undergoing androgen deprivation therapy for prostate cancer","volume":"200","author":"Gild","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgad356","article-title":"Adipose tissue dysfunction in polycystic ovary syndrome","volume":"109","author":"Bril","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0210","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","article-title":"Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle","volume":"105","author":"Cusi","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2024.156066_bb0220","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142241","article-title":"Insulin signaling in health and disease","volume":"131","author":"Saltiel","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2024.156066_bb0225","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12079-019-00512-y","article-title":"Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators","volume":"13","author":"Solarek","year":"2019","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.metabol.2024.156066_bb0230","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3892\/or.2017.5552","article-title":"Inverse relationship between insulin receptor expression and progression in renal cell carcinoma","volume":"37","author":"Takahashi","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.metabol.2024.156066_bb0235","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2019474118","article-title":"Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains","volume":"118","author":"Nagao","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2024.156066_bb0240","first-page":"784","article-title":"The role of insulin-like growth factor axis in bladder cancer: a systemic review and meta analysis","volume":"9","author":"Zhao","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.metabol.2024.156066_bb0245","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0022-5347(05)63999-7","article-title":"Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk","volume":"169","author":"Zhao","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0250","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0090-4295(02)02253-7","article-title":"Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.metabol.2024.156066_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.28.1.120","article-title":"Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance","volume":"28","author":"Sesti","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156066_bb0260","doi-asserted-by":"crossref","first-page":"E1640","DOI":"10.1210\/jc.2011-1227","article-title":"Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I","volume":"96","author":"Arturi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0265","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0270","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11695-007-9087-1","article-title":"IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients","volume":"17","author":"Garcia-Galiano","year":"2007","journal-title":"Obes Surg"},{"key":"10.1016\/j.metabol.2024.156066_bb0275","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2169\/internalmedicine.56.7626","article-title":"The relationship between the growth hormone\/insulin-like growth factor system and the histological features of nonalcoholic fatty liver disease","volume":"56","author":"Chishima","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.metabol.2024.156066_bb0280","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3748\/wjg.v10.i18.2740","article-title":"Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis","volume":"10","author":"Wu","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156066_bb0285","first-page":"543","article-title":"Knockdown of insulin-like growth factor 2 gene disrupts mitochondrial functions in the liver","volume":"13","author":"Gui","year":"2021","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.metabol.2024.156066_bb0290","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2014.01.052","article-title":"Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children","volume":"165","author":"Cianfarani","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.metabol.2024.156066_bb0295","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/cancers15041287","article-title":"Emerging role of IGF-1 in prostate cancer: a promising biomarker and therapeutic target","volume":"15","author":"Liu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.metabol.2024.156066_bb0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","article-title":"Hyperinsulinaemia in cancer","volume":"20","author":"Gallagher","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.metabol.2024.156066_bb0305","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156066_bb0310","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156066_bb0315","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/cd21-0013","article-title":"Association between diabetes and the risk of kidney cancer: systematic review and meta-analysis","volume":"40","author":"Bonilla-Sanchez","year":"2022","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.metabol.2024.156066_bb0320","article-title":"Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2024.156066_bb0325","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.juro.2015.05.097","article-title":"Diabetes mellitus as an independent predictor of survival of patients surgically treated for renal cell carcinoma: a propensity score matching study","volume":"194","author":"Lee","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0330","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4093\/dmj.2014.38.5.330","article-title":"Hyperglycemia as a risk factor for cancer progression","volume":"38","author":"Ryu","year":"2014","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2024.156066_bb0335","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.metabol.2024.156066_bb0340","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-016-3884-9","article-title":"Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals","volume":"59","author":"Carstensen","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2024.156066_bb0345","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2024.156066_bb0350","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156066_bb0355","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2024.156066_bb0360","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0365","unstructured":"U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone. [Last accessed: 06\/02\/2024]."},{"key":"10.1016\/j.metabol.2024.156066_bb0370","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2024.156066_bb0375","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2024.156066_bb0380","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.156066_bb0385","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13300-015-0128-9","article-title":"Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a \u2018case study\u2019","volume":"6","author":"Ptaszynska","year":"2015","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2024.156066_bb0390","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2024.156066_bb0395","doi-asserted-by":"crossref","unstructured":"Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension 2020;75:275\u201384.","DOI":"10.1161\/HYPERTENSIONAHA.119.13419"},{"key":"10.1016\/j.metabol.2024.156066_bb0400","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156066_bb0405","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/HYPERTENSIONAHA.120.14820","article-title":"Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study","volume":"75","author":"Kim","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2024.156066_bb0410","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1681\/ASN.2013060604","article-title":"CKD and the risk of incident cancer","volume":"25","author":"Lowrance","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2024.156066_bb0415","article-title":"Chronic kidney disease is associated with upper tract urothelial carcinoma: a nationwide population-based cohort study in Taiwan","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2024.156066_bb0420","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/HJH.0000000000001286","article-title":"Blood pressure and kidney cancer risk: meta-analysis of prospective studies","volume":"35","author":"Hidayat","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2024.156066_bb0425","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJM200011023431804","article-title":"Obesity, hypertension, and the risk of kidney cancer in men","volume":"343","author":"Chow","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156066_bb0430","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(99)06154-1","article-title":"Cancer in patients on dialysis for end-stage renal disease: an international collaborative study","volume":"354","author":"Maisonneuve","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156066_bb0435","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/ndt\/gfad249","article-title":"Chronic kidney disease and risk of kidney or urothelial malignancy: systematic review and meta-analysis","volume":"39","author":"Brooks","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2024.156066_bb0440","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012092","article-title":"Non-alcoholic fatty liver disease and the risk of urolithiasis: a systematic review and meta-analysis","volume":"97","author":"Qin","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2024.156066_bb0445","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11739-024-03705-5","article-title":"Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis","volume":"19","author":"Mantovani","year":"2024","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.metabol.2024.156066_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109526","article-title":"Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria","volume":"36","author":"Gianmoena","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2024.156066_bb0455","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/qjmed\/hcu195","article-title":"The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis","volume":"108","author":"Cheungpasitporn","year":"2015","journal-title":"QJM"},{"key":"10.1016\/j.metabol.2024.156066_bb0460","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41416-018-0356-7","article-title":"Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands Cohort Study","volume":"120","author":"van de Pol","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.metabol.2024.156066_bb0465","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/89.19.1453","article-title":"Risk of urinary tract cancers following kidney or ureter stones","volume":"89","author":"Chow","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.metabol.2024.156066_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114007","article-title":"Insulin receptor signaling engages bladder urothelial defenses that limit urinary tract infection","volume":"43","author":"Schwartz","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2024.156066_bb0475","first-page":"386","article-title":"Non-alcoholic fatty liver disease is associated with recurrent urinary tract infection in premenopausal women independent of metabolic syndrome","volume":"21","author":"Nseir","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.metabol.2024.156066_bb0480","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/liv.15680","article-title":"Risk of infections in non-alcoholic fatty liver disease: a nationwide population-based cohort study","volume":"43","author":"Shang","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.156066_bb0485","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00345-018-2206-x","article-title":"Chronic urinary tract infection and bladder carcinoma risk: a meta-analysis of case-control and cohort studies","volume":"36","author":"Akhtar","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0490","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00345-018-2257-z","article-title":"Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Bayne","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0495","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/oby.20138","article-title":"Serum leptin and adiponectin levels and risk of renal cell carcinoma","volume":"21","author":"Liao","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2024.156066_bb0500","first-page":"3033","article-title":"The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator","volume":"12","author":"Kashiwagi","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.metabol.2024.156066_bb0505","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4161\/cbt.7.11.6837","article-title":"Concomitant activation of the JAK\/STAT3 and ERK1\/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells","volume":"7","author":"Li","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.metabol.2024.156066_bb0510","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1200\/JCO.2004.06.121","article-title":"Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6\u2014from the Groupe Francais d\u2019Immunotherapie","volume":"22","author":"Negrier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0515","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/bjc.2015.379","article-title":"Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis","volume":"113","author":"Fu","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.metabol.2024.156066_bb0520","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0525","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"Diaz-Montero","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2024.156066_bb0530","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0535","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2353\/ajpath.2010.091218","article-title":"Tumor necrosis factor receptor expression and signaling in renal cell carcinoma","volume":"177","author":"Al-Lamki","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.metabol.2024.156066_bb0540","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/gast.2002.31065","article-title":"Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease","volume":"122","author":"Valenti","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156066_bb0545","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13679-023-00519-y","article-title":"The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease","volume":"12","author":"Vachliotis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.metabol.2024.156066_bb0550","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","article-title":"The role of hepatokines in NAFLD","volume":"35","author":"Stefan","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.156066_bb0555","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0002-9440(10)64285-X","article-title":"Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma","volume":"162","author":"Le Jan","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.metabol.2024.156066_bb0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.urolonc.2016.12.017","article-title":"Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma","volume":"35","author":"Dong","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0565","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/oby.2009.512","article-title":"Adipose depots possess unique developmental gene signatures","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2024.156066_bb0570","doi-asserted-by":"crossref","unstructured":"Chen X, Mao Y, Hu J, Han S, Gong L, Luo T, et al. Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes. Diabetes 2021;70:2322\u201332.","DOI":"10.2337\/db20-1031"},{"key":"10.1016\/j.metabol.2024.156066_bb0575","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.clgc.2021.10.006","article-title":"Perirenal fat as a new independent prognostic factor in patients with surgically treated clear cell renal cell carcinoma","volume":"20","author":"Du","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"157","key":"10.1016\/j.metabol.2024.156066_bb0580","first-page":"e1","article-title":"High perirenal fat thickness predicts a poor progression-free survival in patients with localized clear cell renal cell carcinoma","volume":"36","author":"Huang","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.metabol.2024.156066_bb0585","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.juro.2015.08.105","article-title":"Perirenal fat promotes renal arterial endothelial dysfunction in obese swine through tumor necrosis factor-alpha","volume":"195","author":"Ma","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.metabol.2024.156066_bb0590","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41395-018-0283-5","article-title":"Smoking and the risk of non-alcoholic fatty liver disease: a cohort study","volume":"114","author":"Jung","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156066_bb0595","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2019.07.019","article-title":"Dose-response relationships between cigarette smoking and kidney cancer: a systematic review and meta-analysis","volume":"142","author":"Liu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.metabol.2024.156066_bb0600","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.44430","article-title":"Smoking behaviors and prognosis in patients with non-muscle-invasive bladder cancer in the be-well study","volume":"5","author":"Kwan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2024.156066_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696676","article-title":"Association between alcohol consumption and risk of bladder cancer: a dose-response meta-analysis of prospective cohort studies","volume":"11","author":"Lao","year":"2021","journal-title":"Front Oncol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T05:20:33Z","timestamp":1733808033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524002944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":121,"alternative-id":["S0026049524002944"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156066","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156066"}}